Technology informed by unparalleled Decentralized Trials (DCT) operational experience and delivered at global scale.
Cell and Gene Therapies (CGT) promise critical and transformative benefits to patients. Even with record funding and new launches in this sector, trial and patient journey complexities pose significant barriers to the success and sustainability of these treatments. CGT pioneers require supply chain partnerships that mitigate trial risk and complexity and provide a consultative approach to protocol execution. Let’s explore how to succeed by optimizing pre-trial and pre-screening activities and reducing trial cost and risk with your IRT solution.
Key Takeaways:
Speaker:
Cara Woodruff
Director, Product Management, IQVIA IRT
Technology informed by unparalleled Decentralized Trials (DCT) operational experience and delivered at global scale.
Power your decentralized trial with an agile randomization and trial supply management solution that supports supply flexibility and optimization as well as adaptable direct to patient options.
Explore our library of IRT resources including thought leadership papers, on-demand webinars, case studies, and other valuable content.